More favorable administration, reimbursement could separate latest PCSK9 entrant.
In a cardiovascular portfolio of two, Novartis has had similar post-launch trajectories with Entresto (2015) and this year with Leqvio. Both are first-in-class (Entresto an angiotensin receptor blocker/neutral endopeptidase inhibitor; Leqvio, a first-in-class siRNA); with both having less-than-predicted sales out of the gate. But this time, Novartis CEO Vas Narasimhan has Entresto’s eight-year continued success story (the drug generated $3.5 billion in sales in 2021) and a Leqvio ramp up that is going significantly faster than its predecessor to showcase.
LDL Game Changer: Leqvio
Kommentar
Teilen
